Navigation Links
Signalife Provides Corporate Update
Date:8/31/2007

Friday, August 31, 9:15 am ET

LOS ANGELES, Aug. 31 /PRNewswire-FirstCall/ -- Signalife, Inc. (Amex: SGN), Lowell T. Harmison, President and acting Chief Executive, has release the following corporate update since his matriculation into the Presidency last month:

1. Dr. Harmison has already "cleaned house" and has eliminated several

positions that were producing no revenue whatsoever and no hope of any

positive results for the Company, in his view. That was done

immediately by Dr. Harmison and was done by the Dr. personally. "We

are now operating within five separate departments: Sales, R&D,

Operations, FDA, Regulatory. These positions are now compartmentalized

and operating efficiently under my direct supervision."

2. As promised, and as announced, Dr. Harmison has participated in

obtaining a $102 million financing vehicle for the Company. Dr.

Harmison calls this an "extremely valuable" facility, because it

enables the company to choose the market conditions - and stock price -

at which it shall exchange its stock for capital." Dr. Harmison

continues: "We are thankful to the AMEX for so efficiently and in good

faith evaluating and approving our financing transaction. The market

appears to be getting the message that - when my sales initiatives bear

fruit in the upcoming near term - the obtaining of $100 million at the

market price is a testament to our technology - referred to as a

"modern medical miracle" by NBC. Any other result would have been

unfair to our shareholders, and I promised that I would create a new

era for our shareholders - one with revenues, earnings, profits, growth

and corporate accolades."

3. According to Dr. Harmison, "our sales funnel utilizing marquee

hospitals known to the Company and its Board" is proceeding ahead of

schedule. These are some of the prestigious institutions in the

country and allow the marvelous Fidelity 100 to be utilized in areas

where lives and outcomes can be changed for the better. I anticipate

our market penetration strategy over the next five quarters will

proceed more quickly than I had conservatively anticipated at the

beginning of my tenure."

4. The technology division is also moving on its holter devices as well as

its intra-cardiac monitor - and other devices - with extraordinary

acuity and speed. The division - possibly the core of the Company -

"only gets more efficient as the secrets of the patented technologies

become more known and understood in the quality of the signal from

heart patients of all ages."

"In short, I have achieved more than I anticipated in several short weeks, and the momentum toward device approvals, ventures, sales and earnings are at the center of that gaining momentum. I am still planning on a near-term conference call with the marketplace, but I wish to complete certain touchstone events before having that call. I am always available for shareholder calls and can be reached through our corporate offices," added Dr. Harmison.

About Signalife:

Signalife, Inc. is a life sciences company focused on the monitoring and detection of disease through continuous biomedical signal monitoring. Signalife uses its patented signal technology to design and develop medical devices that simplify and reduce the costs of diagnostic testing and patient monitoring in an ambulatory setting.

Signalife is publicly traded on the American Stock Exchange under the symbol SGN. The website for the company is http://Signalife.com. Clear Data. Trusted Results.

Caution Regarding Forward-Looking Statements:

Statements in this release that are not strictly historical are "forward- looking" statements. Forward-looking statements involve known and unknown risks, which may cause Signalife's actual results in the future to differ materially from expected results. Factors which could cause or contribute to such differences include, but are not limited to, failure to complete the development and introduction of heart monitoring and other biomedical devices incorporating Signalife's technology, failure to obtain federal or state regulatory approvals governing heart monitoring and other biomedical devices incorporating Signalife's technology, inability to obtain physician, patient or insurance acceptance of for heart monitoring and other biomedical incorporating Signalife's technology, and the unavailability of financing to complete management's plans and objectives, including the development of heart monitoring and other biomedical incorporating Signalife's technology. These risks are qualified in their entirety by cautionary language and risk factors set forth and to be further described in Signalife's filings with the Securities and Exchange Commission.


'/>"/>
SOURCE Signalife, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Effectene Transfection Reagent provides efficient gene delivery to primary neuronal cell cultures
2. TSKgel ODS-100Z and TSKgel ODS-100V column series provides a universal solution for the analysis of samples containing acidic, basic, polar & non-polar compounds
3. State provides $200K for Necedah ethanol plant
4. Madison firm provides $200K in capital to tech companies
5. Mirus provides low-cost way to modify genes
6. MDC provides venture funding for tech companies
7. IT Fusion SOS provides outsourced IT aid to small businesses
8. BIO provides forum for Wisconsin to showcase strengths
9. Imago provides atomic probe to Australian lab
10. Online Kiosks provides a new way to send a message
11. Small Tree provides Apple drivers for Intels new 10-gigabit Ethernet cards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 27, 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" or ... its major shareholders, Clean Technology Fund I, LP and ... based venture capital funds which together hold ... a fully diluted, as converted basis), that they have ... entire equity holdings in Biorem to TUS Holdings Co. ...
(Date:6/27/2016)... ... 2016 , ... Parallel 6 , the leading software as a service ... Virtual Patient Encounter CONSULT module which enables both audio and video telemedicine communication ... , Using the CONSULT module, patients and physicians can schedule a face to face ...
(Date:6/27/2016)...  Liquid Biotech USA , ... Sponsored Research Agreement with The University of Pennsylvania ... cancer patients.  The funding will be used to ... clinical outcomes in cancer patients undergoing a variety ... employed to support the design of a therapeutic, ...
(Date:6/24/2016)... 24, 2016 Epic Sciences unveiled a ... susceptible to PARP inhibitors by targeting homologous recombination ... The new test has already been incorporated into ... cancer types. Over 230 clinical trials ... pathways, including PARP, ATM, ATR, DNA-PK and WEE-1. ...
Breaking Biology Technology:
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com ... just published the overview results from the Q1 wave ... the recent wave was consumers, receptivity to a program ... data with a health insurance company. "We ... to share," says Michael LaColla , CEO of ...
(Date:5/3/2016)... 3, 2016  Neurotechnology, a provider of high-precision ... Automated Biometric Identification System (ABIS) , a complete ... MegaMatcher ABIS can process multiple complex biometric transactions ... of fingerprint, face or iris biometrics. It leverages ... and MegaMatcher Accelerator , which have been ...
(Date:4/28/2016)... -- First quarter 2016:   , Revenues ... first quarter of 2015 The gross margin was 49% ... and the operating margin was 40% (-13) Earnings per ... from operations was SEK 249.9 M (21.2) , Outlook ... 7,000-8,500 M. The operating margin for 2016 is estimated ...
Breaking Biology News(10 mins):